Date of Award
6-2024
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Pharmaceutical Sciences
Track
Pharmaceutics
Research Advisor
Wei Li, PhD
Committee
Julio F. Cordero-Morales, PhD; Jianyang Du, PhD; Jianxiong Jiang, PhD; Francesca-Fang Liao, PhD
Keywords
Alzheimer’s disease; TRPC3; calcium ion channel; small molecule inhibitors
Abstract
Alzheimer's disease (AD) is a progressive neurological disorder characterized by extracellular β-amyloid (Aβ) plaques and intracellular tau tangles. The calcium (Ca2+) hypothesis of AD proposes that disrupted intracellular Ca2+ regulation underlies AD pathology, contributing to inflammation, oxidative stress, impaired autophagy, neurodegeneration, and cognitive dysfunction. Store-operated Ca2+ entry (SOCE) maintains ER Ca2+ stores, involving transient receptor potential canonical (TRPC) and Orai channels. Specifically, we speculated that dysregulated functions of TRPC3 contribute to the pathogenesis of AD. We believe that targeting TRPC3 with a pharmacologically feasible agent could prove beneficial in halting cognitive decline. We previously reported compound JW-65, a novel, metabolically stable, brain-penetrative, selective, and safe TRPC3 inhibitor that can directly bind to the TRPC3 protein. We utilized JW-65 as a tool molecule and identified TRPC3 as a unique member of the TRPC family that contributes to the development of AD via the Aβ cascade, in contrast to the predominantly protective role of TRPC6. Preliminary animal studies performed on PS19 mice, a widely studied mouse model of tau pathology, also demonstrated the therapeutic efficacy of JW-65. This finding highlights TRPC3 as a promising therapeutic target for AD. Considering the promising efficacy of JW-65 and the potential for TRPC3-targeted therapy, a panel of JW-65 analogs were synthesized, and their potency and selectivity were characterized. This approach aims to enhance the therapeutic options available for AD treatment.
ORCID
https://orcid.org/0000-0002-3202-2402
DOI
10.21007/aetd.cghs.2024.0006
Recommended Citation
Wang, Jiaxing (https://orcid.org/0000-0002-3202-2402), "Targeting TRPC3: A Promising Therapeutic Strategy for Alzheimer's Disease" (2024). Alternative Theses and Dissertations (AETDs). Paper 6. http://dx.doi.org/10.21007/aetd.cghs.2024.0006.
https://dc.uthsc.edu/aetd/6